Will COVID-19 Derail New Drugs?

Business disruptions due to COVID-19 represent a new risk for investors across all sectors. Expect to see language addressing this added to the risk factors section of 10-K annual reports filed with the Securities and Exchange Commission (SEC).

For biotech and pharma companies, COVID-19 will impede clinical trials and slow down regulatory actions. Here we will explore some of the emerging issues based on what can only be described as a very fluid situation globally.